-
ILCA 2024丨Dr. Stephen L. Chan Shares EMERALD-1 Post-Hoc Analysis on Safety and Efficacy Across Different Treatment Phases and Liver Function Levels
The Phase III EMERALD-1 study has shown that for patients with unresectable intermediate to advanced hepatocellular carcinoma (HCC), the combination of durvalumab, bevacizumab, and transarterial chemoembolization (TACE) significantly improves progression-free survival (PFS) compared to TACE alone. At the 2024 International Liver Cancer Association (ILCA) conference, Dr. Stephen L. Chan from the Faculty of Medicine at…
-
Balancing Toxicity and Efficacy: How Does Combining ADCs with Other Therapies Impact NSCLC Treatment Prospects?
For advanced non-small cell lung cancer (NSCLC), treatment strategies typically include platinum-based doublet chemotherapy, immunotherapy, and targeted therapy, with specific methods determined by molecular biomarker testing. Current unmet medical needs for advanced NSCLC patients include a lack of new treatment options following the failure of immunotherapy combinations, resistance to targeted therapies, and strategies to improve…
-
Optimal Treatment for Resectable NSCLC: Should All Patients Receive Perioperative Immunotherapy?
Recently, several immune checkpoint inhibitor (ICI) regimens have gained regulatory approval for neoadjuvant, adjuvant, and perioperative treatment, transforming the treatment landscape for patients with resectable non-small cell lung cancer (NSCLC). Based on the KEYNOTE-671 study, the perioperative pembrolizumab regimen has been approved for resectable NSCLC in stages II, IIIA, or IIIB (T3-4N2). Is this now…
-
CSCO 2024 | Learning from the Past to Guide the Future: How Biomarker Testing Supports Precision Treatment for Lung Cancer
The 27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting, co-hosted by the Chinese Society of Clinical Oncology and the Beijing Health Management Development Foundation, took place in Xiamen from September 25-29, 2024. During the conference, several lung cancer-focused forums highlighted cutting-edge research and progress in the field both domestically and internationally. During the…
-
ESMO 2024丨Docetaxel Remains Standard Therapy for PD-(L)1 Resistant Advanced NSCLC Patients
Anti-PD-(L)1 therapies have been approved for treating advanced non-small cell lung cancer (NSCLC). However, due to limited options, most patients experience disease progression while on anti-PD-(L)1 therapy. At the 2024 European Society for Medical Oncology (ESMO) Annual Meeting, Dr. Pascale Tomasini from the Multidisciplinary Oncology and Therapeutic Innovations department in Marseille, France, presented findings from…
-
IFSC 2024 | Dr. Daniel G.Tenen from the Cancer Science Institute of Singapore Decodes SALL4 Protein and Cancer
The 9th International Forum on Stem Cells (IFSC) in 2024 focuses on basic stem cell research, regenerative medicine, cell therapy, and the application of clinical research guidelines, gathering experts and scholars from around the world to discuss the latest frontiers in scientific discoveries and technological advancements. During the conference, “Hematology Frontier” specially invited Dr. Daniel…
-
IFSC 2024 | Dr. Simón Méndez-Ferrer Shares New Strategies for the Regulation of the Bone Marrow Microenvironment and the Treatment of Myeloid Malignan
The 9th International Forum on Stem Cells (IFSC) in 2024 focuses on basic stem cell research, regenerative medicine, cell therapy, and the application of clinical research guidelines, gathering experts and scholars from around the world to discuss the latest frontiers of scientific discoveries and technological advancements. During the conference, “Hematology Frontier” specially invited Dr. Simón…
Connecting Medical Expertise through Media
